Malaria Vaccine Shows Potential Breakthrough

The Oxford University team behind the development of a malaria vaccine has revealed it is highly effective.

According to the team, the vaccine is 77 per cent effective in early trials and could be a breakthrough against the disease.

When trialled in 450 children in Burkina Faso, the vaccine was found to be safe and showed “high-level efficacy” over 12 months of follow-up.

Larger trials in nearly 5,000 children between the ages of five months and three years will now be carried out across four African countries to confirm the findings.

Malaria kills more than 400,000 people a year, mostly children in sub-Saharan Africa.

But despite many vaccines being trialled over the years, this is the first to meet the required target.

The World Health Organization estimates there were 229 million cases worldwide in 2019 and 409,000 deaths.

The illness starts with symptoms such as fever, headaches and chills and, without treatment, can progress quickly to severe illness and often death.

Study author Adrian Hill, director of the Jenner Institute and professor of vaccinology at the University of Oxford, said he believed the vaccine was the first to reach the World Health Organization’s goal of at least 75 per cent efficacy.

The most effective malaria vaccine to date had only shown 55 per cent efficacy in trials on African children.

The trials of this malaria vaccine started in 2019, long before coronavirus appeared – and the Oxford team developed its Covid vaccine (with AstraZeneca) on the strength of its malaria research,” Prof Hill said.

A malaria vaccine has taken much longer to come to fruition because there are thousands of genes in malaria compared to around a dozen in coronavirus, and a very high immune response is needed to fight off the disease.

“That’s a real technical challenge,” Prof Hill said. “The vast majority of vaccines haven’t worked because it’s very difficult.”

However, he said the trial results meant the vaccine was “very deployable” and “has the potential to have a major public health impact”.

The Serum Institute of India, which has manufactured the vaccine, says it is confident of delivering more than 200 million doses of the vaccine as soon as it is approved by regulators.